Homepage About Andromeda Product Clinical Trials News Contact Us
Phase III Clinical Trial
Phase I / II Clinical Trials
Clinical Advisory Board

Clinical Trials

Confirmatory Phase III Clinical Study

DIA-AID 2 (DiaPep277® -  Arresting Immune Diabetes)

DIA-AID 2 is a confirmatory phase III study which is ongoing. This study is a global clinical trial which is being conducted at more than 120 clinical study sites.  Patient recruitment has been completed and the study is expected to be completed at the end of 2014.

Eligible patients for the study are between 20 to 45 years of age and within 6 months of diagnosis of type 1 diabetes. Furthermore, the study requires a residual beta cell function when fasting of C-peptide ≥ 0.2nmol/L.

Patients are randomized to 1.0 mg DiaPep277® or placebo with primary endpoint beta cell preservation of function.

Study Steering Committee
  • Prof. Itamar Raz
    Hadassah Medical Center
    Jerusalem, Israel 
     
  • Prof. Paolo Pozzilli
    Università Campus Bio-Medico di Roma
    Rome, Italy

  • Prof. Thomas Linn
    Universitätsklinikum Giessen
    Giessen, Germany

  • Prof. Francois Bonnici
    New Groote Schuur Hospital
    Capetown, South Africa

  • Prof. Philip Raskin
    University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas
    USA
Click on a flag below to find a clinical study site near you.

 
Austria  CzechRepublic  Germany  Belarus  Canada

Israel  Italy  Spain  USA  

Hungary  Lithuania  Poland  Romania

Russia  Serbia  argentina
Would you like to know more?
Click to find out about a clinical study in patients recently diagnosed with Type 1 Diabetes


Websites Design, Development ans SEO Loolweb marketing